0001214659-22-014319.txt : 20221130 0001214659-22-014319.hdr.sgml : 20221130 20221130163018 ACCESSION NUMBER: 0001214659-22-014319 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221129 FILED AS OF DATE: 20221130 DATE AS OF CHANGE: 20221130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jackman Stephan CENTRAL INDEX KEY: 0001864257 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40483 FILM NUMBER: 221435937 MAIL ADDRESS: STREET 1: C/O ALZAMEND NEURO, INC. STREET 2: 3802 SPECTRUM BOULEVARD, SUITE 112C CITY: TAMPA STATE: FL ZIP: 33612 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Alzamend Neuro, Inc. CENTRAL INDEX KEY: 0001677077 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811822909 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: 3500 LENOX RD. NE STREET 2: SUITE 1500 CITY: ATLANTA STATE: GA ZIP: 30326 BUSINESS PHONE: 844-722-6333 MAIL ADDRESS: STREET 1: 3500 LENOX RD. NE STREET 2: SUITE 1500 CITY: ATLANTA STATE: GA ZIP: 30326 4 1 marketforms-57706.xml PRIMARY DOCUMENT X0306 4 2022-11-29 0001677077 Alzamend Neuro, Inc. ALZN 0001864257 Jackman Stephan 3500 LENOX RD NE, SUITE 1500 ATLANTA GA 30326 true true false false Chief Executive Officer Stock Option (Right to Buy) 1.17 2022-11-29 4 A false 2000000 0 A 2032-11-28 Common Stock 2000000 0 D Stock Option (Right to Buy) 1.50 2029-11-17 Common Stock 2000000 0 D Stock Option (Right to Buy) 1.00 2028-11-15 Common Stock 3000000 3000000 D On November 29, 2022, Mr. Jackman was granted options to purchase 2,000,000 shares of common stock of Alzamend Neuro, Inc. (the "Issuer"), of which (i) 50% would vest if the Issuer completed and announced topline data, within three years from the grant date, from a Phase II clinical trial of AL001 that would support a new drug application ("NDA") in Alzheimer's Disease and (ii) 50% would vest if the Issuer completed and announced topline data, within four years from the grant date, from a Phase II clinical trial of ALZN002 that would support an NDA in Alzheimer's Disease. Mr. Jackman was granted options, exercisable for 10 years, to purchase 2,000,000 shares of the Issuer's common stock, of which (i) 50% would vest if the Issuer's common stock closed at or above $10.00 per share for 90 consecutive trading days, and (ii) 10% would vest for each $2.00 per share increment above $10.00 per share for 90 consecutive trading days, with 100% vesting if the Issuer's common stock closed at or above $20.00 per share for 90 consecutive trading days. After November 27, 2026, the number of any unvested shares subject to the option would decrease by 25%. On November 22, 2022, the Issuer modified the vesting criteria of these options to reduce the price targets, which were previously between $10.00 and $40.00 per share, and to extend the period of time for vesting before the 25% of unvested shares subject to the option would be decreased. The stock options vested ratably over 48 months beginning on the date of grant. and are fully vested. /s/ Stephan Jackman 2022-11-30